Division of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, 700 University 6W091, Toronto, Ontario M5G 1Z5, Canada.
Department of Medicine, Princess Margaret Cancer Centre, Suite 5-303C, 610-University Avenue, University of Toronto, Toronto, Ontario M5G 2M9, Canada.
Hematol Oncol Clin North Am. 2021 Apr;35(2):391-407. doi: 10.1016/j.hoc.2020.12.004. Epub 2021 Feb 3.
Myelofibrosis (MF) belongs to a group of clonal stem cell disorders known as the BCR-ABL-negative myeloproliferative neoplasms. Allogeneic hematopoietic stem cell transplantation (HCT) is currently the only curative treatment option for MF. Because HCT can be associated with significant morbidity and mortality, patients need to be carefully selected based on disease-risk, fitness, and transplant factors. Furthermore, in the era of JAK inhibitors, the timing of transplantation has become a challenging question. Here the authors review recent developments in HCT for MF, focusing on risk stratification and optimal timing.
骨髓纤维化（MF）属于一组被称为 BCR-ABL 阴性骨髓增殖性肿瘤的克隆干细胞疾病。异基因造血干细胞移植（HCT）是 MF 的唯一根治性治疗选择。由于 HCT 可能与显著的发病率和死亡率相关，因此需要根据疾病风险、身体状况和移植因素仔细选择患者。此外，在 JAK 抑制剂时代，移植的时机成为一个具有挑战性的问题。本文作者回顾了 MF 患者 HCT 的最新进展，重点关注风险分层和最佳时机。
